Marguron, Inc.

Advancing a Single Shot Cure for HIV-1 Infection

Pioneering innovative strategies to cure life threatening infectious and metabolic disease

Transforming Lives by Developing Curative One Time Treatments

About us

Marguron, Inc. is exploiting breakthrough gene therapy based single shot curative treatments. Our initial focus is preventing and curing HIV-1 infection. 

HIV/AIDS remains one of the most significant infectious disease threats to the population. Globally, 40 million people were living with HIV-1 in 2023. That year saw 1.3 million new infections and 630,000 deaths from AIDS-related diseases. In developed (G9) regions, 3.1 million people live with HIV. While advances in antiretroviral therapy (ART) have markedly improved the outlook for people living with HIV, the stark global statistics reflect the challenges with implementing ART, as well as the realization that this modality is not curative. The advent of long-acting ART formulations is unlikely to provide a permanent solution, as these cost- and resource burdensome therapies require life long administrations.

For this reason, Marguron is disrupting the status quo by developing curative modalities. Our approach is to make reality:

"One Shot and You are Good for Life"

Glowing human DNA is being modified by syringe injection on dark background. Illustration of the concept of genetic engineering and gene therapy
Person wearing a blue and white striped shirt against a plain background.

Ronald Desrosiers, PhD

Co-Founder, Scientific Advisor

Bio
Man in a black suit standing in a laboratory with shelves of glass bottles in the background.

Mario Stevenson, PhD

Co-Founder, Scientific Advisor

Bio
Smiling man in a suit and tie with a blurred floral background.

Raymond Schinazi, PhD, Hon DSc

Co-Founder, Chairman

Bio
Person wearing a light blue checkered shirt, sitting indoors with a blurred background.

Vijai Mohan

Chief Executive Officer

Bio
Smiling person wearing glasses and a dark polo shirt in an office setting.

Bill Ollinger

Vice President - Finance

Bio
Portrait of a man in a suit and tie against a gray background.

Frank Rahmani

Legal Counsel, Partner - Sidley Austin LLP

Bio

Pipeline

Marguron-3A: In Preclinical Development for the Prevention, Treatment and Cure of HIV-1 infections

Harnessing innovations in antibody discovery and the industrialization of gene based medicines, our proprietary treatment used to mitigate the formation of antidrug antibodies (rapamycin, or MRG-01) administered concurrently with AAV9-delivered broadly neturalizing antibodies.

This technology is based on the original and pioneering work performed by Dr. Ronald Desrosiers and his team at the University of Miami whose pre-clinical studies in non-human primates resulted in a key publication on what is now known as "The Miami Monkey". This animal has been free of HIV for over eight years (as of September 2024). Our most recent advance overcomes a key obstacle that could allow millions of people to be cured of their HIV infection. 

Rationale

Antiretroviral management of HIV-1 infection significantly reduces but does not normalize morbidity and mortality. Further, infected individuals want to be cured and free of the stigma that accompanies HIV status - an outcome not currently possible with today's approved therapeutic approaches. Because of the realization that ART alone has not ended the HIV epidemic, there remains a global effort to pursue a practical and scalable solution for HIV infection - one that removes stigmas and one that removes the enduring burdens of this disease.

Target Population

People living with HIV-1 and at risk of HIV infection: 40 million people living with HIV globally; 1.3 million incidence. 3.1 million people living with HIV in developed (G9) nations. 

Extending beyond curative measures, Marguron's technology offers an approach to achieve pre-exposure prophylaxis (PreP) by creating an anbitody shield against infection.

Marguron plans to develop its technology for use in not just developed nations, but also in low and middle income countries (LMICs).

Contact Us

Please use the contact form at the right or email info(at)marguron.com 

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.